 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that KMDA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Kamada (KMDA, $5.85) RSI Indicator left the overbought zone on December 06, 2023

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US...

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB

Kamada extends commercial deal for U.S. distribution; sees $180M rev over first four years...

Kamada extends commercial deal for U.S. distribution; sees $180M rev over first four years

Largest Commercial Agreement in Kamada's History Becomes Effective in January 2024 and Includes $180 Million of Revenues to Kamada Over the First Four Years of the Eight Year TermFinancial Terms...

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB  including $180 Million of Revenues Over First Four Years

Kamada Ltd. (NASDAQ:KMDA  Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $5.06 and traded as low...

Kamada (NASDAQ:KMDA) Stock Passes Below 200-Day Moving Average of $5.06

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Kamada (KMDA Research Report). The associated price target is $11.00...

Promising Revenue Growth and Diverse Portfolio Drive Strong Buy Rating for Kamada: An Analysis by Andrew Fein

In trading on Tuesday, shares of Kamada Ltd (KMDA) crossed above their 200 day moving average of 4.87, changing hands as high as 4.88 per share. Kamada Ltd shares are currently trading up...

KMDA Crosses Above Key Moving Average Level

Kamada beats Q3 top and bottom line estimates; reaffirms FY23 outlook...

Kamada beats Q3 top and bottom line estimates; reaffirms FY23 outlook

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Kamada sees 2023 revenue $138M-$146M, two est. $143.83M

Kamada reports Q3 EPS 7c vs. 1c last year

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Market Cap	$338.52M
Volume (M)	167.00
52-Wk High	$6.35
52-Wk Low	$3.72

Period	Estimated	Reported	Surprise	Result
Q3'23	$0.03	$0.07	119.36%	BEAT
Q2'23	$0.02	$0.04	123.62%	BEAT
Q1'23	$0.03	$0.00	-100.00%	MISSED
Q4'22	$0.07	$0.08	15.67%	BEAT
Q3'22	$-0.03	$0.02	158.54%	BEAT

KMDA Kamada Ltd

About

Feed

News

Sentiment

Earnings

Fundamentals